Z-endoxifen shows promise as new treatment for common breast cancer type
ROCHESTER, Minn. – Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease. This finding was reported from a clinical trial conducted by researchers at Mayo Clinic and the National Cancer Institute, and published in the Journal of Clinical Oncology.
MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.
The final results of a first-in-human phase I study of Z-endoxifen in women with estrogen receptor positive metastatic breast cancer showed that the treatment was safe and resulted in tumor shrinkage in women whose tumors had progressed on standard anti-estrogen therapies, including tamoxifen.
"Tamoxifen, is converted into endoxifen in the liver by an enzyme called CYP2D6. Our previous research found that tamoxifen may be less effective in women with poor CYP2D6 metabolism," says Matthew Goetz, M.D., the study's lead author and an oncologist at Mayo Clinic.
Based on laboratory studies showing that endoxifen better inhibits tumor growth compared to tamoxifen, Dr. Goetz and his colleagues partnered with researchers at the National Cancer Institute to develop Z-endoxifen, an experimental drug unaffected by CYP2D6 metabolism.
"The primary goal of the study was to safely deliver therapeutic levels of endoxifen without the requirement for CYP2D6 liver metabolism," says Dr. Goetz. "However, one of the most surprising observations was the prolonged anticancer benefit, [which] in some cases lasted more than two years in women who had progressed on standard anti-estrogen therapies."
Researchers studied 41 patients with estrogen positive metastatic breast cancer who had progressed on standard anti-estrogen treatments. They concluded that, in patients with metastatic breast cancer who had progressed on standard anti-estrogen treatments, Z-endoxifen provides substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity, and promising anti-tumor activity.
Dr. Goetz and investigators with the Alliance for Clinical Trials in Oncology and the National Cancer Institute recently completed a randomized trial comparing tamoxifen with Z-endoxifen. Results from this trial, A011203, are expected in 2018.
"We are encouraged by these results and [are] hopeful that, based on these data and ongoing studies, Z-endoxifen could become a new U.S. Food and Drug Administration-approved treatment for women with estrogen positive metastatic breast cancer," Dr. Goetz says.
- Vera Suman, Ph.D.
- Joel Reid, Ph.D.
- Don Northfelt, M.D.
- Michael Mahr, M.D.
- Andrew Ralya
- Mary Kuffel
- Sarah Buhrow
- Stephanie Safgren
- Renee McGovern
- John Black, M.D.
- Travis Dockter
- Tufia Haddad, M.D.
- Charles Erlichman, M.D.
- Alex Adjei, M.D., Ph.D.
- Dan Visscher, M.D.
- Zachary Chalmers
- Garrett Frampton
- Benjamin Kipp, Ph.D.
- Minetta Liu, M.D.
- John Hawse, Ph.D.
- James Doroshow
- Jerry Collins
- Howard Streicher
- Matthew Ames, Ph.D.
- James Ingle, M.D.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call the Clinical Trial Referral Office at 1-855-776-0015 (toll-free).
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. For more information, visit mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org.